Molecular imaging agent developer On Target Laboratories has been granted a new technology add-on payment (NTAP) for its Cytalux (pafolacianine) agent from the U.S. Centers for Medicare and Medicaid Services (CMS).
Cytalux is approved in the U.S. for intraoperative use in patients with ovarian cancer and in patients with lung cancer. The agent is used to visualize cancer during surgery using near-infrared imaging.
Under the NTAP, the CMS will provide hospitals with additional payment of up to 65% of the average cost of Cytalux, with a maximum payment of $2,762.50, the company said.
